HIF1A and lung carcinoma: It has been approved by the State Food and Drug Administration of China (CFDA) because of its clinical application on non-small cell lung cancer (NSCLC).23,24 Nevertheless, besides its anti-angiogenesis, it remains unclear whether Endostar also inhibits HIF-1 expression by upregulating MHC class I expression in cancer cells, which is helpful for immunotherapies, including PD-1/PD-L1 inhibitor, to induce effective responses of cell-mediated immunity against cancers such as lung cancer.